Suppr超能文献

脐血来源的诱导多能干细胞形成软骨细胞球

Chondrogenic Pellet Formation from Cord Blood-derived Induced Pluripotent Stem Cells.

作者信息

Nam Yoojun, Rim Yeri Alice, Ju Ji Hyeon

机构信息

CiSTEM Laboratory, Convergent Research Consortium for Immunologic Disease, Division of Rheumatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea.

Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, Institute of Medical Science, College of Medicine, The Catholic University of Korea;

出版信息

J Vis Exp. 2017 Jun 19(124):55988. doi: 10.3791/55988.

Abstract

Human articular cartilage lacks the ability to repair itself. Cartilage degeneration is thus treated not by curative but by conservative treatments. Currently, efforts are being made to regenerate damaged cartilage with ex vivo expanded chondrocytes or bone marrow-derived mesenchymal stem cells (BMSCs). However, the restricted viability and instability of these cells limit their application in cartilage reconstruction. Human induced pluripotent stem cells (hiPSCs) have received scientific attention as a new alternative for regenerative applications. With unlimited self-renewal ability and multipotency, hiPSCs have been highlighted as a new replacement cell source for cartilage repair. However, obtaining a high quantity of high-quality chondrogenic pellets is a major challenge to their clinical application. In this study, we used embryoid body (EB)-derived outgrowth cells for chondrogenic differentiation. Successful chondrogenesis was confirmed by PCR and staining with alcian blue, toluidine blue, and antibodies against collagen types I and II (COL1A1 and COL2A1, respectively). We provide a detailed method for the differentiation of cord blood mononuclear cell-derived iPSCs (CBMC-hiPSCs) into chondrogenic pellets.

摘要

人类关节软骨缺乏自我修复能力。因此,软骨退变并非通过治愈性治疗,而是采用保守治疗。目前,人们正致力于用体外扩增的软骨细胞或骨髓间充质干细胞(BMSC)来再生受损软骨。然而,这些细胞有限的活力和不稳定性限制了它们在软骨重建中的应用。人类诱导多能干细胞(hiPSC)作为再生应用的一种新选择受到了科学界的关注。由于具有无限的自我更新能力和多能性,hiPSC已被视为软骨修复的一种新型替代细胞来源。然而,获得大量高质量的软骨生成微球是其临床应用面临的一项重大挑战。在本研究中,我们使用胚胎体(EB)衍生的贴壁细胞进行软骨生成分化。通过PCR以及用阿尔辛蓝、甲苯胺蓝和抗I型和II型胶原蛋白(分别为COL1A1和COL2A1)抗体染色,证实了软骨生成的成功。我们提供了一种将脐带血单个核细胞衍生的iPSC(CBMC-hiPSC)分化为软骨生成微球的详细方法。

相似文献

引用本文的文献

2
Cell-Based Therapies for Degenerative Musculoskeletal Diseases.基于细胞的退行性肌肉骨骼疾病治疗方法。
Adv Sci (Weinh). 2023 Jul;10(21):e2207050. doi: 10.1002/advs.202207050. Epub 2023 May 18.
9
Current Therapeutic Strategies for Stem Cell-Based Cartilage Regeneration.基于干细胞的软骨再生的当前治疗策略
Stem Cells Int. 2018 Mar 25;2018:8490489. doi: 10.1155/2018/8490489. eCollection 2018.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验